Discovery & development of selective M3 antagonists for clinical use
- 1 February 1997
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 60 (13-14) , 1053-1060
- https://doi.org/10.1016/s0024-3205(97)00047-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonistsLife Sciences, 1995
- Prejunctional muscarinic receptors regulating neurotransmitter release in airwaysLife Sciences, 1995
- Enterocystoplasty in the neuropathic bladderNeurourology and Urodynamics, 1995
- Darifenacin, A selective muscarinic M3 antagonistPharmacological Research, 1995
- Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungsLife Sciences, 1993
- Muscarinic Receptors—Characterization, coupling and functionPharmacology & Therapeutics, 1993
- Muscarinic receptor subtypes in airwaysLife Sciences, 1993
- Differences between the effects of cromakalim and nifedipine on agonist‐induced responses in rabbit aortaBritish Journal of Pharmacology, 1991
- Muscarinic receptor subtypes insubtypes in AirwaysTrends in Pharmacological Sciences, 1988
- A COMPARISON OF AFFINITY CONSTANTS FOR MUSCARINE‐SENSITIVE ACETYLCHOLINE RECEPTORS IN GUINEA‐PIG ATRIAL PACEMAKER CELLS AT 29°C AND IN ILEUM AT 29°C AND 37°CBritish Journal of Pharmacology, 1976